Mullan Pharmaceutical Inc.

Mullan Pharmaceutical Inc., a self-certified small disadvantaged business based in Pasadena, California, supplies harm-reduction medications and vending machine services to federal health agencies and state substance-abuse programs as a sub-recipient on federal grants (87% of recent awards) and as a prime on simplified acquisitions. The vendor operates as a for-profit corporate entity with no awarded federal contract IDVs and no federal contract prime awards; its federal footprint consists of one purchase order from the Indian Health Service and seven grant sub-awards routed through state agencies.

The vendor's customer concentration is split between federal health agencies and state grantees. The Department of Health and Human Services Substance Abuse and Mental Health Services Administration anchors five awards (the count represents 63% of Mullan's recent award volume), with the Department of Justice Office of Justice Programs Bureau of Justice Assistance accounting for two awards and the Indian Health Service accounting for one. The IHS award is the only line item carrying quantified potential value: a $35,400 purchase order for harm reduction vending machine services at Chinle Comprehensive Health Care Facility in Arizona, awarded under simplified acquisition procedures (FAR 12 and FAR 13 commercial items) on May 11, 2026, with performance extending through May 10, 2029. The purchase order sits under NAICS 532490 (commercial and industrial machinery rental and leasing) and PSC W065 (lease or rental of medical, dental, and veterinary equipment and supplies).

Mullan's sub-award footprint centers on naloxone supply and harm-reduction services. The vendor has received six federal grant sub-awards from the Tennessee Department of Mental Health and Substance Abuse Services (prime grantee) between August 2024 and December 2025, including a September 25, 2025 award requiring supply of generic naloxone nasal spray in two 4 mg / 0.1 ml doses, delivery within twenty-four hours (excluding weekends and state holidays) to twenty-three Tennessee addresses, with the vendor maintaining Tennessee pharmacy licensure and functioning as a pharmacy, wholesaler, distributor, or manufacturer. Activity has grown from three awards in 2024 to four in 2025, with one award in 2026 to date. Dollar obligations ($2.4 million across the footprint) significantly outpace quantified potential value ($35 thousand), indicating that sub-award amounts are not fully captured in the source's potential-value field and that Mullan's actual revenue from these grants exceeds the IHS purchase-order figure.